REPORT FROM THE AAN, APRIL 10-17, 2010 – A small retrospective study has examined  the long-term effects of rituximab, a monoclonal antibody directed against CD20+ B cells, in patients with secondary-progressive MS (Ionete et al. AAN, P02.147).